June 27, 2021
Tvardi Therapeutics Raises $74 Million in Series B Financing to Advance Clinical Programs

March 11, 2021
Tvardi Therapeutics Appoints Michael Wyzga, Former CFO of Genzyme, to Board of Directors

June 30, 2021
Tvardi Raises $74M to Advance STAT3 Inhibitors for Cancer, Fibrosis

June 29, 2021
Chasing ‘Holy Grail’ STAT3 Target, Houston Startup Refuels with $74M to Zero in on Liver Cancer

July 06, 2020
Pharmacokinetics and pharmacodynamics of TTI-101, a STAT3 inhibitor that blocks muscle proteolysis in rats with chronic kidney disease

April 26, 2020
Stat3 activation induces insulin resistance via a muscle-specific E3 ubiquitin ligase Fbxo40